Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385521 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL14280453 | 0.90 | PTGS2 (0.82) | PTGS2PTGS1 | |
| SCHEMBL13198633 | 0.80 | PTGS2 (0.82) | PTGS2PTGS1 | |
| SCHEMBL4405855 | 0.78 | PTGS2 (0.64) | PTGS2PTGS1 | |
| Flosulide SCHEMBL29454969 | 0.77 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL13138859 | 0.77 | PTGS2 (0.65) | PTGS2PTGS1 | |
| Flosulide SCHEMBL195509 | 0.77 | PTGS2 (1.00) | PTGS2PTGS1 | |
| Flosulide SCHEMBL29383035 | 0.77 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL7160977 | 0.77 | PTGS2 (0.62) | PTGS2PTGS1 | |
| SCHEMBL6250229 | 0.75 | PTGS2 (1.00) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2796112-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORP (US) | 2023-08-09 | — | — | EP | claimed |
| EP-0927555-B1 | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumours, tumour-related disorders and cachexia | DAIICHI SANKYO CO LTD (JP) | 2011-10-05 | — | — | EP | claimed |
| EP-1390026-B1 | TREATMENT OF HPV CAUSED DISEASES | CORNELL RES FOUNDATION INC (US) | 2010-05-05 | — | — | EP | claimed |
| US-20060154954-A1 | Combinations and use of selected pharmaceutically active compounds | ALTANA PHARMA AG (DE) | 2006-07-13 | — | — | US | claimed |
| US-20060106082-A1 | Nitrooxyderivatives of cyclooxygenase-2 inhibitors | NICOX S.A. (FR) | 2006-05-18 | — | — | US | claimed |
| EP-1599175-A2 | IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS | ALTANA Pharma AG (DE) | 2005-11-30 | — | — | EP | claimed |
| WO-2005074930-A1 | PHARMACEUTICAL COMBINATIONS OF (S) -PANTOPRAZOLE WITH NSAID OR CORTICOSTEROIDS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | claimed |
| WO-2005030224-A1 | NITROSYLATED ANALGESIC AND/OR ANTI-INFLAMMATORY DRUGS HAVING ANTIVIRAL ACTIVITY | NICOX S.A. (FR) | 2005-04-07 | — | — | WO | claimed |
| EP-1517889-A2 | NITROOXYDERIVATIVES OF CYCLOOXYGENASE-2 INHIBITORS | Nicox S.A. (FR) | 2005-03-30 | — | — | EP | claimed |
| JP-2004531514-A | — | — | 2004-10-14 | — | — | JP | claimed |
| WO-2003020268-A1 | METHOD FOR THE TREATMENT AND PREVENTION OF CACHEXIA | WASHINGTON UNIVERSITY (US) | 2003-03-13 | — | — | WO | claimed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| WO-2002080927-A1 | USE OF SELECTIVE COX-2 INHIBITORS FOR THE TREATMENT OF URINARY INCONTINENCE | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2002-10-17 | — | — | WO | claimed |
| WO-2002072106-A2 | COMBINED METHOD FOR TREATING HORMONO-DEPENDENT DISORDERS WITH EXEMESTANE | PHARMACIA ITALIA SPA (IT) | 2002-09-19 | — | — | WO | claimed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | claimed |
| EP-1146905-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | Algos Pharmaceutical Corporation (US) | 2001-10-24 | — | — | EP | claimed |
| EP-1140192-A2 | USE OF A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENTS FOR COMBINATION THERAPY IN NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038730-A2 | USE OF A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENTS FOR COMBINATION THERAPY IN NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000029023-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-05-25 | — | — | WO | claimed |
| EP-0927555-A1 | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumors, tumor-related disorders and cachexia | Sankyo Company Limited (JP) | 1999-07-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | TOP2A, TOP2B, TOP1 | PTGS2 4/4885PTGS1 6/4885 |
| US-20060106082-A1 | Nitrooxyderivatives of cyclooxygenase-2 inhibitors | NOS2, PTGS2, PTGES2 | PTGS2 2/4885PTGS1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.